<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149162</url>
  </required_header>
  <id_info>
    <org_study_id>P030441</org_study_id>
    <secondary_id>AOM 03142</secondary_id>
    <nct_id>NCT00149162</nct_id>
  </id_info>
  <brief_title>Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2</brief_title>
  <acronym>Elam02</acronym>
  <official_title>Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiron Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the interest of maintenance treatment with
      interleukin-2 by randomizing the patients being not allogeneic transplanted in complete
      remission after induction and consolidation chemotherapy concerning the event free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed an open randomized study to evaluate the interest of maintenance treatment with
      interleukin-2 by randomizing the patients being not allogeneic transplanted in complete
      remission after induction and consolidation chemotherapy concerning the event free survival.
      A total of 580 patients will be accrued over 7 years. Treatment consists in subcutaneous
      application of interleukin-2 in treating patients with complete remission by a monthly
      regimen of 5 days during 1 year after having received a chemotherapy consisting of 1
      induction and 3 consolidation treatments.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interest of interleukin-2 in complete remission after induction and consolidation chemotherapy concerning the event free survival (event = relapse of toxic death)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analyze the whole toxicity of the regimen</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the prognostic biological factors</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">580</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated by Proleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without Proleukin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>proleukin</intervention_name>
    <description>One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)
1 cycle of treatment each month during 12 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Proleukin = Interleukin II</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 0 to 18 years

          -  Prior untreated acute myeloid leukemia (AML) of following cytological types : FAB M0,
             M1, M2, M4, M4 eosinophil, M5, M6, M7, without FAB classification or showing
             myelodysplasia (blasts &gt; 20 %)

          -  Isolated myeloid sarcoma

          -  Achieved complete remission

          -  No HLA identical family donor, except for the patients with t(8;21)

          -  No contraindication for the use of interleukin-2

        Exclusion Criteria:

          -  Trisomy 21

          -  Promyelocytic leukemia (M3) or M3 variations

          -  Secondary AML
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Leverger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics Hematology, Children Armand Trousseau Hospital, 26 Avenue Arnold Netter, 75012 Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Leverger, M.D.</last_name>
    <phone>33 1 44 73 60 62</phone>
    <email>guy.leverger@trs.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tabassome Simon, M.D., Ph.D.</last_name>
    <phone>33 1 49 28 22 02</phone>
    <email>urcest@chusa.jussieu.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children Armand Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Auvrignon, M.D.</last_name>
      <phone>33 1 44 73 60 62</phone>
      <email>anne.auvrignon@trs.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Tabassome Simon, M.D., Ph.D.</last_name>
      <phone>33 1 49 28 22 02</phone>
      <email>urcest@chusa.jussieu.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Leverger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lie SO, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Gustafsson G. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol. 1996 Jul;94(1):82-8.</citation>
    <PMID>8757513</PMID>
  </reference>
  <reference>
    <citation>Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol. 1994 Nov;12(11):2367-77.</citation>
    <PMID>7964952</PMID>
  </reference>
  <reference>
    <citation>Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21;324(12):808-15.</citation>
    <PMID>1997853</PMID>
  </reference>
  <reference>
    <citation>Mertens AC, Wen W, Davies SM, Steinbuch M, Buckley JD, Potter JD, Robison LL. Congenital abnormalities in children with acute leukemia: a report from the Children's Cancer Group. J Pediatr. 1998 Nov;133(5):617-23.</citation>
    <PMID>9821417</PMID>
  </reference>
  <reference>
    <citation>Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997 Apr;15(4):1544-52.</citation>
    <PMID>9193351</PMID>
  </reference>
  <reference>
    <citation>Béhar C, Suciu S, Benoit Y, Robert A, Vilmer E, Boutard P, Bertrand Y, Lutz P, Ferster A, Tokaji E, Manel AM, Solbu G, Otten J. Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872. Med Pediatr Oncol. 1996 Mar;26(3):173-9.</citation>
    <PMID>8544799</PMID>
  </reference>
  <reference>
    <citation>Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998 Mar 7;351(9104):700-8.</citation>
    <PMID>9504514</PMID>
  </reference>
  <reference>
    <citation>Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec;17(12):3767-75.</citation>
    <PMID>10577848</PMID>
  </reference>
  <reference>
    <citation>Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999 Apr 1;85(7):1506-13. Review.</citation>
    <PMID>10193940</PMID>
  </reference>
  <reference>
    <citation>Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol. 2001 May 15;19(10):2705-13.</citation>
    <PMID>11352963</PMID>
  </reference>
  <reference>
    <citation>Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarini A, Lista P, Pegoraro L, Mandelli F, Forni G, et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol. 1990 May;75(1):34-40.</citation>
    <PMID>2375921</PMID>
  </reference>
  <reference>
    <citation>Leblanc T, Berger R. Molecular cytogenetics of childhood acute myelogenous leukaemias. Eur J Haematol. 1997 Jul;59(1):1-13. Review.</citation>
    <PMID>9260575</PMID>
  </reference>
  <reference>
    <citation>Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood. 1991 Nov 1;78(9):2182-7.</citation>
    <PMID>1932739</PMID>
  </reference>
  <reference>
    <citation>Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood. 1994 Oct 1;84(7):2158-63.</citation>
    <PMID>7919330</PMID>
  </reference>
  <reference>
    <citation>Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J, Thuret I, Bergeron C, Bordigoni P, Esperou-Bourdeau H, Perel Y, Vannier JP, Schaison G. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant. 1996 Feb;17(2):191-6.</citation>
    <PMID>8640165</PMID>
  </reference>
  <reference>
    <citation>Michel G, Baruchel A, Tabone MD, Nelken B, Leblanc T, Thuret I, Bordigoni P, Bergeron C, Esperou-Bourdeau H, Perel Y, Vannier JP, De Lumley L, Dommergues JP, Lamagnère JP, Couillaud G, Auvrignon A, Schaison G, Leverger G. Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther. 1996 Apr;38(2):169-76.</citation>
    <PMID>8931998</PMID>
  </reference>
  <reference>
    <citation>Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood. 1986 Oct;68(4):938-48.</citation>
    <PMID>3489494</PMID>
  </reference>
  <reference>
    <citation>Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B, Gandemer V, Schmitt C, Lamagnere JP, De Lumley L, Bader-Meunier B, Couillaud G, Schaison G, Landman-Parker J, Thuret I, Dalle JH, Baruchel A, Leverger G; Group LAME of the French Society of Pediatric Hematology and Immunology. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant. J Clin Oncol. 2002 Jun 15;20(12):2774-82.</citation>
    <PMID>12065553</PMID>
  </reference>
  <reference>
    <citation>Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, Versteeg C, Hammond GD. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol. 1993 Mar;11(3):538-45.</citation>
    <PMID>8445429</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Therese Ngoue</name_title>
    <organization>Direction Interregionale de la Recherche Clinique, Ile de France, APHP</organization>
  </responsible_party>
  <keyword>Controlled</keyword>
  <keyword>Multicenter</keyword>
  <keyword>International</keyword>
  <keyword>Randomized study</keyword>
  <keyword>Direct individual benefit</keyword>
  <keyword>complete remission after chemotherapy</keyword>
  <keyword>non allogeneic transplanted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

